American group Eli Lilly renews its confidence in its French production facility

By announcing in October 2023 a new investment of €160 million in its Fegersheim site (Grand Est region), the American pharmaceutical group Eli Lilly has once again shown its commitment to the skills of its teams based in the Grand Est region and the quality of its production of injectable medicines.

In operation since 1967, this site had already benefited from nearly €500 million in investments in recent years, with this new announcement set to consolidate its positions in the group’s industrial network.

Now more than ever, Lilly intends to strengthen its leadership in the treatment of diseases, such as diabetes and obesity, which are unfortunately on the rise in our societies. Fegersheim is one of the flagship sites of the Eli Lilly Group.

Proof of its employees’ operational excellence is the fact that the Fegersheim production site, at the cutting-edge of digitalized and robotic technology, will welcome two new latest-generation, high-speed production lines. This will enable it to enter a new phase of its development and to further assert itself as a site capable of manufacturing the most innovative therapeutic solutions. Lily’s decision to choose France serves as a perfect example of France’s ability and that of French manufacturers to respond to the challenges of sovereignty in terms of public healthcare.

“Pride and responsibility”

“Securing this investment here in Fegersheim is a source of great pride for us. This decision by our parent company rewards the commitment and expertise of every one of our employees and the operational excellence of the site, which, for the last ten years, has been moving towards more digitalized and eco-friendly manufacturing processes. It also forces us to remember: we are fully aware that, beyond its impact in terms of industrial sovereignty and the particularly innovative dimension of the solutions that we are going to put on the market, this investment also brings hope in terms of public healthcare. We will live up to the trust placed in us by both the Eli Lilly Group and the public authorities.”

Marcel Lechanteur - CEO Lilly France and Benelux